RESUMEN
Fungemia is common in critically ill patient populations, and is associated with a high rate of mortality, especially when caused by nonalbicans Candida species. Herein, we describe a fatal case of fungemia following cardiothoracic surgery in which the organism, initially identified as Candida inconspicua, represents a novel species: Pichia alaskaensis.
Asunto(s)
Fungemia , Pichia , Humanos , Fungemia/microbiología , Fungemia/diagnóstico , Resultado Fatal , Pichia/aislamiento & purificación , Masculino , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Antifúngicos/uso terapéutico , Anciano , Persona de Mediana Edad , FemeninoRESUMEN
We retrospectively evaluated antimicrobial stewardship program (ASP) interventions over a 63-month period. We compared acceptance rates for those interventions communicated telephonically versus those communicated with a temporary note left in the electronic medical record. Telephonic communication produced superior acceptance rates overall and when analyzed by intervention type and provider.
Asunto(s)
Programas de Optimización del Uso de los Antimicrobianos , Antibacterianos/uso terapéutico , Comunicación , Humanos , Estudios RetrospectivosRESUMEN
PURPOSE: A case of vancomycin enzyme immunoassay (EIA) interference confirmed by high-performance liquid chromatography (HPLC) is described. SUMMARY: Therapeutic drug monitoring is standard of practice in vancomycin dosing and monitoring in order to maximize the pharmacodynamic effects and minimize toxicity. After a 52-year-old woman received 5 doses of vancomycin, serum concentrations continued to rise for several days in the absence of ongoing vancomycin administration. Despite persistently elevated vancomycin concentrations, the patient clinically deteriorated and required treatment with an alternative agent. Subsequently, serum concentrations were processed via HPLC and analyzed for percent protein binding. Confirmatory analysis revealed substantially lower concentrations by HPLC than were obtained by EIA and an abnormal elevation in protein binding. After discharge from the index admission, the patient returned 11 months later and had a dectectable vancomycin concentration by EIA prior to receipt of vancomycin. HPLC analysis confirmed the true concentration was undetectable. Though the exact interfering substance was not identified, the above discrepancy in concentrations between the two assay methods indicates the presence of assay interference, and adds to the available literature suggesting similar occurrences. This case is particularly troubling given that the level of interference was not such that it would lead a clinician to immediately suspect interference, and the patient experienced treatment failure. CONCLUSION: Falsely elevated values for serum vancomycin concentration, measured by EIA, contributed to treatment failure in a patient. The substance presumably responsible for EIA interferences was not identified.
Asunto(s)
Antibacterianos/sangre , Monitoreo de Drogas/métodos , Técnicas para Inmunoenzimas , Vancomicina/sangre , Cromatografía Líquida de Alta Presión , Reacciones Falso Positivas , Femenino , Humanos , Persona de Mediana Edad , Insuficiencia del TratamientoRESUMEN
An Alaska Native hunter developed fever, swollen finger, and septic hips after harvesting seals. Evaluation of hip tissue by 16S rRNA gene polymerase chain reaction and sequencing revealed a putative novel mycoplasma species. We report the identification of this organism and describe the first known case of disseminated seal finger mycoplasmosis.
Asunto(s)
Artritis Infecciosa/diagnóstico , Artritis Infecciosa/microbiología , Dedos/patología , Cadera/patología , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/microbiología , Mycoplasma/clasificación , Adulto , Alaska , Análisis por Conglomerados , ADN Bacteriano/química , ADN Bacteriano/genética , ADN Ribosómico/química , ADN Ribosómico/genética , Dedos/microbiología , Cadera/microbiología , Humanos , Masculino , Datos de Secuencia Molecular , Mycoplasma/aislamiento & purificación , Pelvis/diagnóstico por imagen , Filogenia , ARN Ribosómico 16S/genética , Radiografía Abdominal , Análisis de Secuencia de ADN , Tomografía Computarizada por Rayos XRESUMEN
Consumption of undercooked game meat during pregnancy is considered a risk factor for congenital toxoplasmosis, but cases definitively linking ingestion of infected meat to clinical disease are lacking. We report a confirmed case of congenital toxoplasmosis identified because of atrial flutter in the fetus and linked to maternal consumption of Toxoplasma gondii PCR-positive moose meat.
Asunto(s)
Aleteo Atrial/parasitología , Ciervos , Enfermedades Fetales/parasitología , Enfermedades Transmitidas por los Alimentos/parasitología , Complicaciones Infecciosas del Embarazo/parasitología , Toxoplasmosis Congénita/diagnóstico , Toxoplasmosis Congénita/etiología , Adulto , Animales , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Carne/parasitología , EmbarazoRESUMEN
BACKGROUND: Antiretroviral therapy (ART) in resource-limited settings (RLSs) is monitored clinically and immunologically, according to World Health Organization (WHO) or national guidelines. Revised WHO pediatric guidelines were published in 2010, but their ability to accurately identify virological failure is unclear. METHODS: We evaluated performance of WHO 2010 guidelines and compared them with WHO 2006 and Cambodia 2011 guidelines among children on ≥6 months of first-line ART at Angkor Hospital for Children between January 2005 and September 2010. We determined sensitivity, specificity, positive and negative predictive values, and accuracy using bootstrap resampling to account for multiple tests per child. Human immunodeficiency virus (HIV) resistance was compared between those correctly and incorrectly identified by each guideline. RESULTS: Among 457 children with 1079 viral loads (VLs), 20% had >400 copies/mL. For children with WHO stage 1/2 HIV, misclassification as failure (met CD4 failure criteria, but VL undetectable) was 64% for WHO 2006 guidelines, 33% for WHO 2010 guidelines, and 81% for Cambodia 2011 guidelines; misclassification as success (did not meet CD4 failure, but VL detectable) was 11%, 12%, and 12%, respectively. For children with WHO stage 3/4 HIV, misclassification as failure was 35% for WHO 2006 guidelines, 40% for WHO 2010 guidelines, and 43% for Cambodia 2011 guidelines; misclassification as success was 13%, 24%, and 21%, respectively. Compared with WHO 2006 guidelines, WHO 2010 guidelines significantly increased the risk of misclassification as success in stage 3/4 HIV (P < .05). The WHO 2010 guidelines failed to identify 98% of children with extensive reverse-transcriptase resistance. CONCLUSIONS: In our cohort, lack of virological monitoring would result in unacceptable treatment failure misclassification, leading to premature ART switch and resistance accumulation. Affordable virological monitoring suitable for use in RLSs is desperately needed.